Top

Published in:

01-02-2018 | Gynecologic Oncology

Oncotype DX^® in breast cancer patients: clinical experience, outcome and follow-up—a case–control study

Authors: Michelle G. Rath, Lorenz Uhlmann, Marita Fiedler, Joerg Heil, Michael Golatta, Christine Dinkic, Andre Hennigs, Sarah Schott, Veronika Ernst, Thorsten Koch, Christof Sohn, Cosima Brucker, Joachim Rom

Published in: Archives of Gynecology and Obstetrics | Issue 2/2018

Abstract

Purpose

Breast cancer is the leading cause of death from cancer in women and the most common cancer in the world [1]. To date, many patients with estrogen-receptor-positive (ER+) breast cancer are overtreated with chemotherapy when the rationale for adjuvant chemotherapy is based on clinicopathologic parameters. Different studies were able to demonstrate that a 21-gene expression assay (Oncotype DX^® Genomic Health, Redwood City, CA) can predict the benefit from adjuvant chemotherapy in ER+ breast cancers [2, 3] and provide additional prognostic information independent of clinicopathological features [4].

Results

Data from all patients with ER+ Her2neu− breast cancer undergoing Oncotype DX^® testing between 2011 and 2014 at a tertiary referral center in Germany were analyzed. Oncotype DX^® was performed in 69 cases, in 2 cases data were missing and in 3 cases Oncotype DX^® could not be performed by the company. The results showed a low risk in 39 cases, an intermediate risk in 22 cases and a high risk in 3 cases. Based on Oncotype results, treatment recommendations were changed in 39 of 64 patients (61%). Before Oncotype DX^® testing, chemotherapy was recommended in 67 patients, afterwards only in 25 patients. Data from 44 of 67 patients were matched to controls for stage, tumor grade, menopausal and hormone receptor status. Within a mean observation time of 19.7 months, cancer recurrence was observed in two patients.

Conclusions

Oncotype DX^® testing can be recommended for risk-tailored chemotherapy. Results should be validated in larger prospective studies.

Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19(8):1893–1907. https://doi.org/10.1158/1055-9965.EPI-10-0437 CrossRefPubMed

Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF, Breast Cancer Intergroup of North A (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11(1):55–65. https://doi.org/10.1016/S1470-2045(09)70314-6 CrossRefPubMed

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23):3726–3734. https://doi.org/10.1200/JCO.2005.04.7985 CrossRefPubMed

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826. https://doi.org/10.1056/NEJMoa041588 CrossRefPubMed

Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics. CA Cancer J Clin 64(1):9–29. https://doi.org/10.3322/caac.21208 CrossRefPubMed

Early Breast Cancer Trialists’ Collaborative G (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717. https://doi.org/10.1016/S0140-6736(05)66544-0 CrossRef

Early Breast Cancer Trialists’ Collaborative G, Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784. https://doi.org/10.1016/s0140-6736(11)60993-8 CrossRef

Sparano JA, Paik S (2008) Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26(5):721–728. https://doi.org/10.1200/JCO.2007.15.1068 CrossRefPubMed

DX O. http://breast-cancer.oncotypedx.com/

10.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, Panel M (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747. https://doi.org/10.1093/annonc/mdr304

11.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr, American Society of Clinical O (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287–5312. https://doi.org/10.1200/jco.2007.14.2364 CrossRefPubMed

12.

Gligorov J, Pivot XB, Jacot W, Naman HL, Spaeth D, Misset JL, Largillier R, Sautiere JL, de Roquancourt A, Pomel C, Rouanet P, Rouzier R, Penault-Llorca FM, Francilian Breast I (2015) Prospective Clinical utility study of the use of the 21-gene assay in adjuvant clinical decision making in women with estrogen receptor-positive early invasive breast cancer: results from the SWITCH study. Oncologist 20(8):873–879. https://doi.org/10.1634/theoncologist.2014-0467 CrossRefPubMedPubMedCentral

13.

Smyth L, Watson G, Walsh EM, Kelly CM, Keane M, Kennedy MJ, Grogan L, Hennessy BT, O’Reilly S, Coate LE, O’Connor M, Quinn C, Verleger K, Schoeman O, O’Reilly S, Walshe JM (2015) Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland. Breast Cancer Res Treat 153(3):573–582. https://doi.org/10.1007/s10549-015-3555-4 CrossRefPubMed

14.

Carlson JJ, Roth JA (2013) The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat 141(1):13–22. https://doi.org/10.1007/s10549-013-2666-z CrossRefPubMedPubMedCentral

15.

Gyanchandani R, Lin Y, Lin HM, Cooper K, Normolle DP, Brufsky A, Fastuca M, Crosson W, Oesterreich S, Davidson NE, Bhargava R, Dabbs DJ, Lee AV (2016) intratumor heterogeneity affects gene expression profile test prognostic risk stratification in early breast cancer. Clin Cancer Res 22(21):5362–5369. https://doi.org/10.1158/1078-0432.CCR-15-2889 CrossRefPubMedPubMedCentral

Title: Oncotype DX® in breast cancer patients: clinical experience, outcome and follow-up—a case–control study
Authors: Michelle G. Rath
Lorenz Uhlmann
Marita Fiedler
Joerg Heil
Michael Golatta
Christine Dinkic
Andre Hennigs
Sarah Schott
Veronika Ernst
Thorsten Koch
Christof Sohn
Cosima Brucker
Joachim Rom
Publication date: 01-02-2018
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 2/2018
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-017-4618-z

At a glance: The STEP trials

Springer Medicine

Oncotype DX^® in breast cancer patients: clinical experience, outcome and follow-up—a case–control study

Abstract

Purpose

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

Bipolar vessel-sealing devices in laparoscopic hysterectomies: a multicenter randomized controlled clinical trial

Re: Estimation of neonatal outcome artery pH value according to CTG interpretation of the last 60 min before delivery: a retrospective study. Can the outcome pH value be predicted?

The role of serum ADAMTS-1 and aggrecan on polycystic ovary syndrome in adolescents and younger-aged females

Circulating levels of specific members of chromosome 19 microRNA cluster are associated with preeclampsia development

Predictors of cerclage failure in patients with singleton pregnancy undergoing prophylactic cervical cerclage

Diagnostic performance of HPV E6/E7 mRNA assay for detection of cervical high-grade intraepithelial neoplasia and cancer among women with ASCUS Papanicolaou smears